Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
$10.9M Hold
112,483
0.78% 24
2017
Q3
$10M Buy
112,483
+17,043
+18% +$1.3M 0.65% 35
2017
Q2
$6.92M Buy
95,440
+69
+0.1% +$4.64K 0.42% 63
2017
Q1
$6.21M Sell
95,371
-214
-0.2% -$13.5K 0.34% 79
2016
Q4
$5.99M Sell
95,585
-28,460
-23% -$1.74M 0.41% 62
2016
Q3
$7.82M Buy
124,045
+23,730
+24% +$1.54M 0.56% 47
2016
Q2
$6.21M Sell
100,315
-18,685
-16% -$1.14M 0.47% 64
2016
Q1
$6.8M Sell
119,000
-51,445
-30% -$2.87M 0.42% 69
2015
Q4
$10.1M Sell
170,445
-711,909
-81% -$41M 0.6% 39
2015
Q3
$48M Sell
882,354
-2,280
-0.3% -$148K 1.2% 16
2015
Q2
$59.4M Buy
884,634
+483,875
+121% +$31.6M 1.26% 9
2015
Q1
$23.5M Buy
400,759
+178,414
+80% +$10.8M 0.67% 32
2014
Q4
$14.6M Sell
222,345
-200,000
-47% -$12.6M 0.44% 62
2014
Q3
$24.4M Buy
422,345
+128,118
+44% +$7.11M 0.65% 28
2014
Q2
$16.6M Buy
294,227
+55,488
+23% +$2.91M 0.49% 42
2014
Q1
$12.3M Buy
+238,739
New +$12.1M 0.41% 69

Other funds holding ABBV

GLG LLC's ABBV Position: Q4 2017 in Review

GLG LLC held its AbbVie (ABBV) position steady in Q4 2017 at 112,483 shares worth $10.9M. The position accounts for 0.78% of the portfolio, ranked #24.

GLG LLC first reported a position in ABBV in Q1 2014 and has held it in 16 quarters since. The position peaked at $59.4M in Q2 2015. 2,000 funds tracked by Wall St. Rank hold ABBV as of Q4 2017.

  • GLG LLC held 112,483 shares of AbbVie worth $10.9M as of Q4 2017.
  • GLG LLC left its AbbVie share count unchanged in Q4 2017.
  • AbbVie made up 0.78% of GLG LLC's portfolio in Q4 2017, its #24 holding.
  • GLG LLC first reported a position in AbbVie in Q1 2014 and has held it in 16 quarters since.
  • GLG LLC's AbbVie position peaked at $59.4M in Q2 2015.
  • 2,000 funds tracked by Wall St. Rank held AbbVie as of Q4 2017.

Based on GLG LLC's 13F filing for Q4 2017, filed 14 Feb 2018.